GLP-1 Agonists Drive 7.3% U.S. Health Spending Increase to $5.7 Trillion in 2025

Government data published in Health Affairs document that Americans increased physician visits, hospital procedures, and prescription fills at rates exceeding prior forecasts. GLP-1 drugs for diabetes and weight management emerged as a distinct spending category, with list prices near $1,000 monthly per patient and rapid uptake across commercial and Medicare populations. This pattern compounds an already elevated price base, pushing health care’s share of GDP higher and amplifying premium growth for employers and individuals.

The surge connects directly to macroeconomic pressures: employer-sponsored insurance premiums rose faster than wages, while Medicare Part D reinsurance costs climbed due to high-cost GLP-1 claims. Observational CMS National Health Expenditure accounts and commercial claims analyses both show these agents now rival top therapeutic classes in total outlays, shifting resources away from other chronic-disease management and raising cost-sharing for non-GLP-1 users.

Continued expansion will hinge on 2026–2027 formulary negotiations and potential IRA price negotiations. If net prices remain above $600 monthly after rebates, total GLP-1 spending could exceed $40 billion annually, forcing further trade-offs in state Medicaid budgets and commercial stop-loss coverage.

Next steps require granular claims data linking utilization to clinical outcomes and total cost offsets to determine whether downstream savings materialize at scale.